Evidence map›Paper›PMID 41466260›Full record

ArticleJournal of nanobiotechnology2025

An oral engineered cerium-peptide composite microsphere inhibits inflammatory bowel disease and reverses chronic fibrosis​​.

Wenyu Qiao, Luling Yang, Yu Liu, Huaiyuan Zhang, Zhihuan Zheng, Tianheng Gu, Jiaxi Zhu, Xinyi Hu, Gangze Li, Yuxia Zhang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Biomaterial-based therapeutic strategies for oral submucous fibrosis.Frontiers in cell and developmental biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wenyu Qiao *Center of Emergency & Intensive Care Unit, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Luling Yang *Digestive Endoscopy Center, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200336, China.
Yu Liu *Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Huaiyuan Zhang *Department of Orthopedics, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Zhihuan ZhengFuzhou Neuropsychiatric Hospital, Fujian Medical University, Fujian, 350008, China.
Tianheng GuCenter of Emergency & Intensive Care Unit, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Jiaxi ZhuCenter of Emergency & Intensive Care Unit, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Xinyi HuDepartment of General Practice, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Gangze LiCenter of Emergency & Intensive Care Unit, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Yuxia ZhangCenter of Emergency & Intensive Care Unit, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Meng XiaoCenter of Emergency & Intensive Care Unit, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Lin ZhangCenter of Emergency & Intensive Care Unit, Jinshan Hospital, Fudan University, Shanghai, 201508, China. linzhang0315@fudan.edu.cn.

Funding

Key Discipline of Shanghai Municipal Health System 2024ZDXK0012Research Project of Shanghai Municipal Health Commission 202340280
6 · The paper itself

Abstract

Excessive accumulation of reactive oxygen species (ROS) and dysbiosis of the gut microbiota are pivotal contributors to the pathogenesis of inflammatory bowel disease (IBD) and associated fibrosis. In this study, a microfluidic approach was utilized to fabricate a multifunctional therapeutic microsphere system by encapsulating hollow mesoporous cerium oxide nanoparticles (HCeO

Indexed as

CeriumInflammatory Bowel DiseasesMicrospheresPeptidesAdministration, OralAnimalsAnti-Inflammatory AgentsAntioxidantsColitisDextran SulfateDisease Models, AnimalFibrosisGastrointestinal MicrobiomeHumansMaleMiceAnti-Inflammatory AgentsAntioxidantsceric oxideCeriumDextran SulfatePeptidesReactive Oxygen SpeciesTransforming Growth Factor betaAlginate microspheresCeO2 nanozymeFibrosis inhibitionInflammatory bowel diseaseIntestinal inflammationMicrobiota modulationTGF-β/Smad inhibition

Identifiers

PMID41466260
PMCPMC12752269

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.